Abstract

Quasi-optical beamformer (1) comprising. -a plurality N > 1 of powei feeds (PF), each of the i c [1;N] power feeds (PF) being configured to emit a respective radio-frequency beam denoted Ri, - a radio-frequency transmission line (LT) fed at a first end by the power feeds and comprising at a second end a plurality of network ports (PR) that are configured to collect radio-frequency radiation, the transmission line (LT) comprising a radio-frequency waveguide (GO) that comprises at least two metal plates (PM) that are stacked so as to guide the radio-frequency beams Ri, i c [1; IV] towards the network ports (PR), the lransmission line (LT) extending along a cenlral main axis denoted axis x, - a first reflector (M1) having a first centre (C1) centred on the axis x and a first effective radius of curvature and being configured to reflect the guided radio-frequency beams Roi c [1; N], - a second reflector (M2) having a second effective radius of curvature and being configured to reflect the radio-frequency beams (RF) reflected by the first reflector so as to direct them towards the network ports so as to form output radio-frequency beams (RSi), the first and second effective radii of curvature and an arrangement of the power feeds (PF) with respect to the first reflector being configured so that - each of the output radio-frequency beams (RS,) is a plane wave, and - a transverse amplitude distribution Ai, on the network ports (PR), of each output radio-frequency beam (RS), is substantially identical

IPC Classes  ?

• H01Q 19/17 - Combinations of primary active antenna elements and units with secondary devices, e.g. with quasi-optical devices, for giving the antenna a desired directional characteristic using reflecting surfaces wherein the surfaces are concave the primary radiating source comprising two or more radiating elements
• H01Q 15/14 - Reflecting surfaces; Equivalent structures
• H05K 1/02 - Printed circuits - Details

Abstract

A recombinant SARS-CoV-2 S glycoprotein ectodomain trimer is disclosed, comprising three recombinant protomers each containing at least the SARS- CoV-2 S glycoprotein ectodomain, and wherein: in each protomer, the furin cleavage site is inactivated/disrupted; Arg408 of one of said protomers is covalently linked to Lys378 of another one of said protomers; and Lys947 of one of said protomers is covalently linked to Arg1019 and/or to Lys776 of another one of said protomers.

IPC Classes  ?

• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus

Abstract

What is proposed is a device (300) for controlling radiofrequency beams of a given polarization, the device comprising a set of at least one cell (400), comprising a support frame (420) and at least one interconnection (460) internal to the frame. The frame is inscribed within a prism, having a given axis Z' and Ar faces connected to one another by Ar edges oriented along the axis Z'. The frame comprises Ar corner elements, each having a rim coincident with an edge and being arranged such that the frame has, on each face, a slot (440-n) extending along the axis Z'. The interconnection comprises Ar inductive rods (462-n), each comprising two ends of which a first end is connected to a rim, the second ends being connected to one another at a connection point positioned in the centre of the frame in a plane orthogonal to the axis Z'. Each cell is configured to carry out polarization- invariant transmission and/or reflection of beams.

IPC Classes  ?

• H01Q 15/10 - Refracting or diffracting devices, e.g. lens, prism comprising three-dimensional array of impedance discontinuities, e.g. holes in conductive surfaces or conductive discs forming artificial dielectric

Abstract

The present invention relates to a prognostic risk score for a chemosensitive cancer, in particular acute myeloid leukemia (AML), based on somatic genetic abnormalities that affect certain genes in the mitochondrial genome.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The invention relates to a method for selecting data from an electroencephalogram (EEG), in the form of a set of starting scalograms, each scalogram being calculated from a portion of an electroencephalographic signal, said method comprising: - a step of extracting, by means of an artificial neural network, a set of candidate scalograms (Esc); for the candidate scalograms (Sc) from the set of candidate scalograms (Esc): - a step of calculating characteristics of the electroencephalographic signal portion (So) corresponding to the candidate scalogram (Sc); and - when the plurality of characteristics are within prerequisite value ranges, a step of selecting the electroencephalographic signal portion (So) of the candidate scalogram (Sc) within an electroencephalographic signal selection data structure.

IPC Classes  ?

• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

The present application is directed to a device which serves to capture microparticles in suspension in the air and which has no active means of ventilation and no means of electrical energy supply. The device comprises a structured support traversed by a large number of openings with a minimum dimension of between 1 millimetre and 15 mm, the structured support having a void fraction of greater than 80%, the structured support being coated with a medium for capturing the microparticles in suspension in a flow of air, the medium being chosen from among: vegetable oils, mineral oils, synthetic or semi-synthetic oils, water-soluble lubricants, silicone oils, animal fat, the structured support coated with the capturing medium being configured to be traversed by a flow of air at a linear speed of between 0.1 and 5 m/s without causing a pressure drop of more than 300 Pa, preferably without causing a pressure drop of more than 250 Pa. The present application is also directed to a method for capturing microparticles in suspension in the air and to the use of the device, more particularly in an underground network for transporting passengers by rail.

IPC Classes  ?

• B01D 46/00 - Filters or filtering processes specially modified for separating dispersed particles from gases or vapours
• B01D 46/10 - Particle separators, e.g. dust precipitators, using filter plates, sheets or pads having plane surfaces

Abstract

According to a first aspect, the present description relates to a quantum simulator (200) to simulate an evolution of a solution of a complex nonlinear equation. The quantum simulator comprises a first wavelength-tunable laser (201) configured to emit light with a tunable central wavelength; a vapor cell (205) comprising a gas of atoms or molecules at a given temperature; a beam shaper unit (203) arranged between said wavelength-tunable laser and said vapor cell and configured to modify the phase and/or the amplitude of the emitted light. The vapor cell is configured to receive light at the output of said beam shaper unit so that said light interacts with said gas to produce an output light; said interaction mapping the complex nonlinear equation with given initial conditions (21) and coefficient data (22) of said complex nonlinear equation. The quantum simulator further comprises a wavefront detector (207) configured to detect amplitude and/or phase of at least a portion of a wavefront of said output light and a processing unit (208) configured to calculate, from said phase and/or amplitude of the detected wavefront, output data (23) comprising a value of the solution of the complex nonlinear equation.

IPC Classes  ?

• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

The present invention concerns a new method based on the combination of a particular osmotic swelling, an adapted and controlled plasma membrane lysis and removal, to produce said giant extracellular organelles vesicles, and use of said giant extracellular organelles vesicles to screen the activity of proteins or exogenous molecules.

IPC Classes  ?

• A61K 9/127 - Liposomes
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

The present invention relates to a system (1) for guiding a user, comprising a portable computer terminal (2) and a stereophonic audio device (3) that is intended to be associated with the head of the user (5), the terminal and the device communicating with each other wirelessly. The audio device (3) is equipped with inertial sensors and with a binaural rendering engine. The portable computer terminal (2) comprises software that generates guiding-instruction data associating a description of an audio signal to be delivered, and an indication relative to the virtual position of this audio signal. The binaural rendering engine generates a spatialized audio signal (41), which is delivered to the user (5) by the audio device (3), depending on the guiding-instruction data, transmitted by the portable computer terminal (2) via wireless communication, and on data of the inertial sensors (3).

IPC Classes  ?

• G01C 21/20 - Instruments for performing navigational calculations

Abstract

The present invention relates to devices and methods for transporting and monitoring light beams, especially for so-called "lensless" endo-microscopic imaging. The present invention is for example applicable to endoscopic exploration, for example of organs of a living being whilst the latter is able to move freely during the measurement. More particularly, the present invention allows the transmission matrix of the fibre to be measured "directly", whilst the fibre potentially undergoes changes of configuration. The present invention also relates to a fibre-optic device suitable for implementing the method.

IPC Classes  ?

• G01M 11/00 - Testing of optical apparatus; Testing structures by optical methods not otherwise provided for

Abstract

The present invention relates to benzimidazole derivatives and pharmaceutical compositions comprising such benzimidazole derivatives, for use in the treatment or prevention of a histiocytosis or a craniopharyngioma.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/00 - Drugs for dermatological disorders
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The invention relates to a dihydrogen injection device (2) having a longitudinal axis (X), intended to be mounted on an annular base of an annular combustion chamber (4) of a turbomachine, comprising an inner channel (6) for circulating dihydrogen, and an annular outer channel (8) for circulating a mixture at least comprising air, the inner channel (6) and the annular outer channel (8) being coaxial, an inner swirler (14) being provided in the inner channel (6) and an outer swirler (28) being provided in the annular outer channel (8), a downstream end (16) of the inner channel (6) being arranged upstream, at a distance r, from a downstream end (24) of the annular outer channel (8). Such combustion of dihydrogen makes it possible to eliminate carbon-containing polluting emissions such as carbon monoxide, unburned hydrocarbons or fine particles and smoke particles.

IPC Classes  ?

• F23R 3/14 - Air inlet arrangements for primary air inducing a vortex by using swirl vanes
• F23D 14/24 - Non-premix gas burners, i.e. in which gaseous fuel is mixed with combustion air on arrival at the combustion zone with separate air and gas feed ducts, e.g. with ducts running parallel or crossing each other at least one of the fluids being submitted to a swirling motion

Abstract

The invention relates to a degradable intrauterine system for the prolonged release of an active ingredient in the uterine cavity comprising (a) a degradable A and B block copolymer, wherein the A block is a polyester, the B block is a poly(oxyethylene) (PEO) with a weight-average molecular weight of greater than or equal to 50 kDa; and the ethylene oxide unit/ester unit molar ratio is between 0.05 and 5; (b) at least one polyester homopolymer; and (c) at least one active ingredient intended to be released in the uterine cavity. The invention also relates to a kit comprising at least one intrauterine system according to the invention and means for inserting the system into the uterine cavity.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61L 27/00 - Materials for prostheses or for coating prostheses
• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/58 - Materials at least partially resorbable by the body

Abstract

The present invention relates to the combination of a miR-17mimic and a miR-340 mimic for use for the prevention and/or treatment of cancer, in particular for the treatment of glioblastoma. In particular, said combination additionally comprises a miR-222 antagomiR.

IPC Classes  ?

• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a calibration device for optical imaging applications, comprising a body (1) forming separate areas (11-19) and a polymeric material visible in a spectral range of wave-lengths comprised between 500 nm and 2000 nm included arranged on said areas.

IPC Classes  ?

• G01J 3/52 - Measurement of colour; Colour measuring devices, e.g. colorimeters using colour charts
• G06T 7/90 - Determination of colour characteristics
• G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection

Abstract

The present invention relates to novel peptides having the same motif LRIRX1TYX2, where X1 is selected from amino acids A or F; and X2 is selected from amino acids G or K. The present invention also relates to their use in the treatment of skin changes of various origins, to pharmaceutical and cosmetic compositions comprising them, and to a cosmetic method. More particularly, the treatment of said changes consists in reinforcing the dermal-epidermal junction, cell-matrix and/or cell-cell adhesion and cell migration in the epidermis, and in promoting the repair of the skin surface.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 8/64 - Proteins; Peptides; Derivatives or degradation products thereof
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)

Abstract

The present invention relates to compounds of formula (I), wherein: - A is an anti-cancer agent, - Y is an electron-withdrawing or electron-donating group, - L represents a linker -A1-A2-A3-A4-A5-A6-. A1, A3 and A5 representing a (C1-C6) alkylene radical, A2 representing a group obtained by click chemistry, A4 being a (C1-C32) alkylene radical interrupted by at least one oxygen atom, A6 being a radical selected from the group consisting of: -NRc-, -O- and -S-, Rc representing H or a (C1-C12) alkyl group, and - L' is a radical capable of reacting with an amino, hydroxy or thiol function.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

Method for determining the level of inorganic pyrophosphate (PPi) in a biological sample, comprising a) a measurement of the concentration of PPi in a first fraction of the biological sample, using an assay based on enzymatic reaction b) a measurement of the concentration of PPi in a second fraction of the biological sample, using an assay based on ionic chromatography c) a comparison of the value measured in step a) and the value measured in step b), and assessing if the difference is above a pre-determined threshold. If the difference between the values measured respectively in step a) and in step b) is lower than or equal to the pre-determined threshold, the concentration of PPi in the biological sample is determined as the mean of said values measured in step a) and in step b).

IPC Classes  ?

• C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The invention relates to a method for generating nanoparticles on the surface of a substrate, said method comprising: - a step of providing the substrate made of a material comprising at least one element from columns 4, 5, 13 and 14 of the periodic table, and at least one noble or transition metal; - a step of laser-irradiating the substrate with a pulse duration of between 1 fs and 100 ps, a fluence per pulse of between 0.01 J/cm2 and 100 J/cm2, a wavelength of between 100 nm and 5000 nm, and a number of pulses per point of between 1 and 1000; and - a step of generating at least one nanoparticle on the surface of the substrate, the at least one nanoparticle comprising at least the noble or transition metal, and having a chemical composition different from that of the substrate. The invention also relates to a part comprising such nanoparticles.

IPC Classes  ?

• B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing electromagnetic waves
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• B23K 26/062 - Shaping the laser beam, e.g. by masks or multi-focusing by direct control of the laser beam
• B23K 26/082 - Scanning systems, i.e. devices involving movement of the laser beam relative to the laser head
• B23K 26/352 - Working by laser beam, e.g. welding, cutting or boring for surface treatment
• B23K 26/00 - Working by laser beam, e.g. welding, cutting or boring
• C21D 10/00 - Modifying the physical properties by methods other than heat treatment or deformation
• C22F 3/00 - Changing the physical structure of non-ferrous metals or alloys by special physical methods, e.g. treatment with neutrons
• C23C 14/14 - Metallic material, boron or silicon
• C23C 14/16 - Metallic material, boron or silicon on metallic substrates or on substrates of boron or silicon
• C23C 14/35 - Sputtering by application of a magnetic field, e.g. magnetron sputtering
• C23C 14/58 - After-treatment

Abstract

A device (12) for wireless detection of a BTEX component in a soil (14) saturated with water, comprising an antenna (24), a permeable enclosure (26), and a sensor (28) located in the enclosure. The sensor comprises: - a piezoelectric substrate (36) comprising lithium tantalate, - an interdigitated transducer (IDT) connected to the antenna for producing surface acoustic waves (40), - a first mirror (M1 ) for a first echo (E1 ) of the acoustic waves, - a second mirror (M2) for producing a second echo (E2), - a first layer (41 ) of a first polymer between the transducer and the second mirror, the first polymer being adapted for reacting with the BTEX component so as to modify a travel speed of the second echo, and - a first guiding layer (43) comprising a metal and/or a polymer and located between the transducer and the first mirror.

IPC Classes  ?

• G01N 29/02 - Analysing fluids
• G01N 29/024 - Analysing fluids by measuring propagation velocity or propagation time of acoustic waves
• G01N 29/24 - Probes
• G01N 29/30 - Arrangements for calibrating or comparing, e.g. with standard objects
• G01N 29/32 - Arrangements for suppressing undesired influences, e.g. temperature or pressure variations

Abstract

The invention relates to a signal detector (10), in particular for radio-frequency signals, in particular a ?Wake Up Radio? detector, comprising: - a first circuit (20) which receives the signal as its input and is configured to set the operation point (M) at its output at a predefined DC voltage (Vm_DC) to which a variable part (?Vm) that is dependent on the signal of the input is added; and - a second circuit (30) which is connected at its input to the output of the first circuit (20) and is configured to amplify the variable part (?Vm) of the signal, this second circuit comprising a chain of at least two cascading logic inverters (32) that operate below the threshold.

IPC Classes  ?

• H04B 1/24 - Circuits for receivers in which no local oscillation is generated the receiver comprising at least one semiconductor device having three or more electrodes
• H04W 52/02 - Power saving arrangements

Abstract

The invention relates to the field of patient's care and describes method and systems, for prediction of mortality, functional outcome and recovery after status epilepticus, based on machine classifiers and logistic regression functions, and using biological markers and variables easily obtainable in intensive care units.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

System for detecting an antigen comprising: - a first fusion protein with no luciferase activity comprising: -a N-terminal domain which comprises a first single domain antibody which is directed against a first epitope of said antigen and -a C-terminal domain which comprises a first fragment of a luciferase having the amino acid sequence SEQ ID NO: 1 or is a variant thereof and - a second fusion protein with no luciferase activity comprising: -a N-terminal domain which comprises a second single domain antibody which is directed against a second epitope of said antigen and -a C-terminal domain which comprises a second fragment of a luciferase having the amino acid sequence SEQ ID NO: 2 or is a variant thereof. Luminescence is emitted in the presence of a substrate when both the first fusion protein and the second fusion protein bind to said antigen.

IPC Classes  ?

• C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
• G01N 33/542 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X, R1, R2, R3 are defined, a conjugate thereof and their uses as drug or research tools.

IPC Classes  ?

• C07D 303/48 - Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
• A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61K 31/396 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 35/00 - Antineoplastic agents
• C07C 243/34 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a carbon skeleton further substituted by nitrogen atoms
• C07D 203/08 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Abstract

The present invention relates to novel serotonin derivatives of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. Another object of the present invention relates to the use of compound of formula (I) as a drug, in particular in the prevention and/or the treatment of iron overload-associated disorders.

IPC Classes  ?

• C07D 209/16 - Tryptamines
• A61K 31/4045 - Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• A61P 7/06 - Antianaemics

Abstract

The invention relates to a current switcher comprising: - a positive supply bus (18) and a negative supply bus (20); - a floating-output current amplifier (22) configured to make flow, as output, an intermediate current dependent on a flowing setpoint current applied as input; - at least one anodic reference dipole (24) connected between the positive supply bus (18) and the floating-output current amplifier (22); - at least one cathodic reference dipole (26) connected between the floating-output current amplifier (22) and the negative supply bus (20); and - at least two stimulation bridges (28), each stimulation bridge (28) comprising an anodic current source (34) and a cathodic current source (36) each configured to copy the intermediate current.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

The present invention relates to a population of small extracellular vesicles (sEVs) for use in the treatment of obesity in a subject in need thereof, wherein the sEVs comprise at least one polynucleotide encoding a D168A dominant negative AMP-activated protein kinase alpha 1 (AMPKal-DN) mutant protein operably linked and under the control of a steroidogenic factor 1 (SF1) promoter, wherein the sEVs are engineered to transiently express in their outer membrane at least one fusion protein comprising the neurotrophic rabies virus (RVG) peptide fused to lysosome-associated membrane protein 2b. Said population is highly safe and effective, as the sEVs, when administered systematically, are capable of exerting their effect in the SF1 expressing neurons located in the ventromedial nucleus of the hypothalamus.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• C12N 5/0784 - Dendritic cells; Progenitors thereof
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• A61P 3/04 - Anorexiants; Antiobesity agents
• C12N 15/52 - Genes encoding for enzymes or proenzymes

Abstract

A method is disclosed for processing photoacoustic images, this method comprising: obtaining (110) a time series of images of a sample, said images being acquired by a photoacoustic imaging system at Mx excitation-pulse wavelengths, with N images acquired per wavelength; performing (120) multispectral spatio-temporal filtering via singular value decomposition applied to all of the N*Mx acquired images so as to obtain N*Mx filtered images; for each wavelength, computing (140) a filtered variance image based on the N filtered images, a pixel of coordinate r in the filtered variance image being equal to the variance of the distribution of the values of pixels of same coordinate r in the filtered images obtained for this wavelength; and correcting (150A) the filtered variance image by subtracting a variance of the residual electronic noise after the multispectral spatio-temporal filtering has been performed, said noise being produced by the sensors of ultrasonic waves of the photoacoustic imaging system.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

The invention relates to a scanning dynamic collimator device (SDD) for minibeam production. The SDD comprises a single slit collimator being mounted on a support. The SDD is arranged to translate the collimator in a plane perpendicular to a plane whereby the single slit extends and/or in a direction parallel to the plane whereby the single slit extends and/or to rotate the collimator relative to a rotation axis parallel to the plane whereby the single slit extends and to tilt the collimator relative to a predefined reference axis and/or relative to a point comprised in the single slit.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

The invention relates to a cell (10) for a power generation device (1), which comprises: - two compartments (100, 101) intended respectively to receive fluids (F1, F2) that each have a different concentration of a predetermined ion, which compartments are separated by a membrane (105) allowing the predetermined ion to pass through; and - two adsorbent layers (107) of the predetermined ion placed respectively on either side of the membrane. The invention also relates to two power generation devices incorporating such a cell, and to a method for operating one of these devices.

IPC Classes  ?

• H01M 8/22 - Fuel cells in which the fuel is based on materials comprising carbon or oxygen or hydrogen and other elements; Fuel cells in which the fuel is based on materials comprising only elements other than carbon, oxygen or hydrogen
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells

Abstract

The present invention is based on the finding that Netrin-(1) is retained in a stickier manner in the cell matrix at the cell periphery of the cancer cells, whereas Netrin-(1) is expressed in adults specifically in some tumors. It is also shown herein that Netrin-(1) is expressed very early during tumor formation. This makes Netrin-(1) an unexpected very specific target for imagery and/or targeted therapy. The present invention thus relates to compounds comprising an anti-Netrin-1 antibody, especially NP(137), a chelating moiety, optionally associated with a radioisotope, and their use either in imagery, diagnosis, especially companion diagnosis, or in targeted therapy. New diagnostic tests, which may be companion tests, and new cancer therapies, that may be combined to the companion test, are also proposed.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61K 51/10 - Antibodies or immunoglobulins; Fragments thereof

Abstract

The tumoral stroma evolution during cancer is playing a key role as it may acts as a physical barrier limiting access of the immune cells to the tumor. Thus, ?ig-h3 (TGF?i) overexpression in the stroma is of bad prognosis in Pancreatic Ductal Adenocarcinoma and in other cancers. A monoclonal antibody against ?ig-h3 protein called 18B3 was shown playing a role in directly modulating the anti-tumoral immune response by blocking inhibiting CD8+ T cell activation. From 18B3 the inventors developed humanized antibodies having unexpectedly high affinity, slow dissociation rate and strong thermal stability making them powerful candidates for treating cancers wherein the stroma expresses ?ig-h3 in vivo. The invention thus relates to these humanized monoclonal antibodies and methods of treatment of such cancers.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

The present invention relates to a method for producing a mixture of alkoxylated polyphenols that can be used directly for producing different polyurethane materials, in particular polyurethane foams.

IPC Classes  ?

• C08G 18/18 - Catalysts containing secondary or tertiary amines or salts thereof
• C08G 18/30 - Low-molecular-weight compounds
• C08G 18/32 - Polyhydroxy compounds; Polyamines; Hydroxy amines
• C08G 18/64 - Macromolecular compounds not provided for by groups
• C08G 18/65 - Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
• C08G 18/76 - Polyisocyanates or polyisothiocyanates cyclic aromatic
• C08J 9/14 - Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent organic
• C08L 75/06 - Polyurethanes from polyesters
• C08L 75/08 - Polyurethanes from polyethers

Abstract

The present invention relates to an in vitro method for characterising a tumour, based on the quantitative analysis of modified and unmodified nucleosides from the total cellular RNA, from the extracellular RNA and/or from the isolated nucleosides, extracted from a biological sample. More particularly, the invention relates to a method for predicting the grade of a glial tumour. More particularly, the invention also relates to a method for detecting a tumour. The present invention therefore lies in the fields of cancerology and molecular biology, more particularly applied to medical diagnosis.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

Computer-implemented method for assisting a general anesthesia or a sedation of a subject, comprising : - receiving an electroencephalogram EEG signal of a subject, - processing the EEG signal comprising ?-bands for -- defining for each instant of a plurality of instants, a part of the signal comprised in a time window comprising the instant, the part of the signal being related to the instant, -- determining for each instant, a distribution of a power of the part of the signal as a function of the frequency, -- determining for each instant a maximum power frequency as a frequency of maximum power in the distribution, the maximum power frequency being related to the instant, -- detecting a reference instant, so that the maximum power frequency as a function of time takes higher values before the reference instant than after,-- detecting in a time frame following the reference instant, an alpha instant corresponding to a first occurrence of a suppression of an ?-band, - estimating a first parameter as the duration between the reference instant and the alpha instant, said first parameter relating to a sensitivity of the subject to a general anesthesia or sedation.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves

Abstract

The present invention relates to recombinant variants of R-spondin proteins and their use as a medicament, in particular for the treatment of diabetes.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals

Abstract

The invention relates to a method for the identification of at least one microorganism present in a sample, based on the detection of peptides issued from the cleavage of ribosomal proteins of said microorganism, comprising the following steps: a) lysis of microorganism(s) and cleavage of the proteins present in said sample, to obtain a mixture of peptides, b) decomplexing said peptides mixture using a liquid separation device coupled with a mass spectrometer, c) nebulizing the liquid eluted from the separation device using an ion source, in order to produce an ion current, d) receiving said ion current from the ion source using said mass spectrometer and, for each cycle of a plurality of cycles, executing on the ion current a series of filtering steps for detecting a transition, said transition comprising a precursor ion and at least one fragment ion of said precursor ion, said transition being read from a predefined list of transitions using the mass spectrometer, wherein for each transition of the series, the mass spectrometer selects and fragments a precursor ion of the each transition; e) receiving data concerning a plurality of transitions to be used to monitor the mixture of peptides using the processor, f) assigning said plurality of transitions into two or more contiguous groups of transitions, into said predefined list of transitions, using the processor, g) monitoring at least one sentinel transition associated with one sentinel compound in each group of the two or more contiguous groups, wherein said at least one sentinel transition is selected as having the latest expected retention time in the group, using the processor, h) when the signal of at least one sentinel transition of a group is detected with the mass spectrometer, starting the monitoring of at least one sentinel transition in a next contiguous group while stopping the monitoring of the transitions of the preceding group, using the processor, i) optionally, generating a chromatogram or electropherogram, from the detection of transitions read from a predefined list with said mass spectrometer, using the processor, wherein each transition read from the predefined listed is associated to a peptide, and wherein the microorganism is identified according to the detection of said peptide(s).

IPC Classes  ?

• G01N 30/86 - Signal analysis
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

Novel compounds derived from schweinfurthins G, E and F The present invention relates to novel compounds derived from schweinfurthins of formula (I): (I). The invention also relates to pharmaceutical compositions containing them and also to the use thereof for the prevention, inhibition and/or treatment of cancers, neurodegenerative diseases, dyslipidaemia, hypercholesterolaemia, parasitic diseases and/or viral diseases and to processes for preparing them.

IPC Classes  ?

• C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/4192 - 1,2,3-Triazoles
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents
• C07D 311/80 - Dibenzopyrans; Hydrogenated dibenzopyrans
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 493/04 - Ortho-condensed systems

Abstract

Compound of the 7a,8,9,10,11,11a-hexahydro-1H,7H-pyrano[2,3-c]xanthene type, method of preparation thereof, intermediates thereof and therapeutic applications thereof. The present invention relates to compounds of formula (I) in which R0 represents O or N-ORa, R1 is OH or protected OH, R2 R3 R4 represent, independently, a C1-C4 alkyl, R5 represents OH, a protected OH, -O-P(=O)(OH)2, a sugar, H, a halogen, -CF3, a C1-C4 alkyl, a C2-C4 alkenyl or a C2-C4 alkynyl, R6 represents H, OH, protected OH, -O-P(=O)(OH)2, or a sugar, R7 represents H, OH, protected OH, a halogen, a C1-C4 alkyl, a C2-C4 alkenyl, a C2-C4 alkynyl, a triazolyl, -O-Rb, N(Rc)(Rd), -C(=O)-N(Re)(Rf), -O-C(=O)-N(Rg)(Rh), and R8, R9, R10, and R11 are, independently, H, OH or protected OH. The present invention further relates to the method of preparation thereof, the intermediates thereof and the therapeutic applications thereof.

IPC Classes  ?

• C07D 493/04 - Ortho-condensed systems
• A61P 31/12 - Antivirals

Abstract

The present invention concerns a new method for the preparation of a Li-P-S-O product, as well as the products obtainable by said methods, and uses thereof especially as solid electrolytes.Figure: non

IPC Classes  ?

• C01D 15/00 - Lithium compounds
• H01M 10/052 - Li-accumulators
• H01M 10/0562 - Solid materials
• C01B 17/22 - Alkali metal sulfides or polysulfides
• C01B 25/14 - Sulfur, selenium, or tellurium compounds of phosphorus

Abstract

Systems and methods for generating an action strategy to be executed by an autonomous system are disclosed. The action strategy comprises a series of actions to be performed by the autonomous system to accomplish a corresponding active objective in response to detecting an abnormal event, the abnormal events occurring or having occurred in an environment where the autonomous system is configured to operate. The method comprises accessing a first database populated with event descriptions corresponding to abnormal events and accessing a second database populated with candidate objectives. Each candidate objective defines a task accomplishable by the autonomous system and comprises an activation condition and a progressive task unit structure describing a hierarchy of actions to be performed in order to accomplish the corresponding candidate objective. An execution of a candidate objective generating an action strategy from the progressive task unit structure of the active objective and executing the action strategy.

IPC Classes  ?

• G06N 5/02 - Knowledge representation; Symbolic representation
• G06N 20/00 - Machine learning

Abstract

The invention relates to a pancreatic cell receiving matrix (1) comprising a semi-permeable wall (10) and a porous body (12) comprising a first set (120) of cavities (1200) comprising pancreatic cells (13), and a second set (121) of cavities (1210) free of pancreatic cells. The first set (120) of cavities and the second set (121) of cavities are not fluidically connected to one another. The cavity or cavities (1210) left free of cells create paths for the nutrients and gases to diffuse in the matrix (1), and they form a nutrient and gas reserve area in the matrix. The matrix (1) limits and preferably prevents nutrient and gas depletion of the pancreatic cells (13). Their mortality is therefore reduced, allowing better insulin delivery.

IPC Classes  ?

• A61F 2/02 - Prostheses implantable into the body

Abstract

The invention relates to an optoelectronic component (1) that is insensitive to dislocations, comprising: - a semiconductor heterostructure (2) able to emit laser radiation, said semiconductor heterostructure being formed from first semiconductors comprising a cascade of gain-providing active regions (21) in which the inter-band radiative transition is of type II, and - a carrier structure (30) comprising a non-native substrate (3) different from the first semiconductors, said semiconductor heterostructure (2) being formed by epitaxial growth on the carrier structure (30), wherein the active regions have a dislocation density higher than 107.cm-2. Figure for the abstract: Fig. 1

Abstract

A system and a method for generating a navigation path for an autonomous system. The method comprises receiving data comprising characteristics of entities, the entities defining an environment in which the autonomous system is configured to operate; receiving first instructions causing the autonomous system to identify a destination in the environment; generating a navigation path comprising waypoints to be followed by the autonomous system to reach the destination, the waypoints being generated based on the characteristics of the entities and defining segmental paths; executing second instructions causing the autonomous system to navigate along the navigation path; and upon navigating from a first waypoint to a second waypoint: accessing updates of the characteristics of the entities located in a vicinity of a corresponding segmental path; generating a sub-path between the first waypoint and the second waypoint based on second information; and navigating along the sub-path to reach the second waypoint.

IPC Classes  ?

• G06N 5/02 - Knowledge representation; Symbolic representation
• G06Q 10/047 - Optimisation of routes or paths, e.g. travelling salesman problem

Abstract

Methods of and systems for knowledge-based reasoning to establish a list of active objectives by an autonomous system. The method comprises accessing a list of active objectives; accessing a first database populated with static environment properties, the static environment properties defining properties of entities, the entities defining an environment in which the autonomous system is configured to operate; accessing a second database populated with dynamic environment properties comprising third computer-readable instructions generated by the autonomous system based on events having been observed by the autonomous system. Upon observing a new event, a new dynamic environment property is generated based on the new event and coherence checking is executed to assess whether the new dynamic environment property conflicts with at least one of the static environment properties, and, if so, the new dynamic environment property being identified as incoherent.

IPC Classes  ?

• G06N 5/02 - Knowledge representation; Symbolic representation
• G06N 20/00 - Machine learning

Abstract

Systems and methods for managing an execution of an action strategy by an autonomous system are disclosed. The action strategy comprises a series of actions to be performed by the autonomous system to accomplish a corresponding active objective. The method comprises identifying, by a processor of the autonomous system, an active objective to be accomplished 5 by the autonomous system, the active objective describing a hierarchy of actions to be performed to accomplish the corresponding active objective. The method comprises generating, by the processor, an action strategy from the hierarchy of actions of the active objective, the actions of the action strategy corresponding to the actions of the hierarchy of actions of the active objective and executing the action strategy. Upon completion of an 0 execution of an action, the processor provides data comprising information relating to a state of completion of the action strategy.

IPC Classes  ?

• G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
• G06N 3/00 - Computing arrangements based on biological models
• G06N 5/02 - Knowledge representation; Symbolic representation
• G06N 7/00 - Computing arrangements based on specific mathematical models
• G06N 20/00 - Machine learning

Abstract

The invention relates to a method for imaging an object to be imaged (O), characterised in that it comprises: - generating, by a lighting device (2), a series of lighting patterns; - for each lighting pattern, performing a simulation phase, wherein translations of the lighting pattern are performed at the input of a multimode optical fibre having a square cross-section (4) by means of at least one translation device (3a) of an optical system (3) arranged between the lighting device (2) and the input of the multimode optical fibre having a square cross-section (4), the translations being performed in a plane parallel to the input plane of the multimode optical fibre having a square cross-section (4); - for each simulation phase, performing an acquisition phase, wherein the signal generated by the lighting pattern on the object to be imaged (O) located at the output of the multimode optical fibre having a square cross-section (4) is measured by a signal measuring device (5; 9); and - reconstructing, by a computing device (6), using the measured signal for each of the acquisition phases, the object to be imaged (O).

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor

Abstract

The present invention relates to a tactile stimulation interface (10), comprising a tactile face and a second face (8) equipped with at least one actuator (1a, 1b, 1c, 1d), the interface (10) being characterized in that the second face (8) comprises at least one acoustic wave confinement area (11), the confinement area (11) being defined by at least one acoustic mirror (9) made of an acoustic metamaterial configured to reflect acoustic waves of frequencies within a predetermined interval, called the band gap, the interface (10) furthermore being characterized in that each acoustic mirror (9) and each actuator (1a, 1b, 1c, 1d) comprises a system configured to generate and transmit acoustic waves to the tactile face (7) and to prevent the propagation of acoustic waves of frequencies within the band gap.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

The present invention relates to a combination comprising at least one monoamine reuptake inhibitor and at least one potassium-chloride cotransporter type 2 expression-enhancing compounds (KEEC). The present invention also relates to a pharmaceutical composition comprising at least one monoamine reuptake inhibitor and at least one KEEC, and to a kit of parts comprising at least one monoamine reuptake inhibitor and at least one KEEC, as a combined preparation for simultaneous, separate or sequential use.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Abstract

The present invention relates to a composition comprising: - either at least ethyl-?-D-glucuronide, the ethyl part of which comprises at least one non-radioactive isotope (or ethyl-?-D-glucuronide probe) and at least ethyl-?-D-galactopyranoside (or ethyl-?-D-galactopyranoside probe), the ethyl part of which comprises at least one non-radioactive isotope; - or at least ethyl-?-mannopyranoside, the ethyl part of which comprises at least one non-radioactive isotope (or ethyl-?-D-glucuronide probe); for use thereof as a diagnostic and/or prognostic agent.

IPC Classes  ?

• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

The present invention relates to a process for consolidating a hydrogel comprising alginate and gelatin, which includes a step of consolidation by crosslinking of the hydrogel using a suitable solution, in order to give it particularly advantageous mechanical properties. The present invention also relates to the use of this crosslinking solution for consolidating the structure of a hydrogel comprising alginate and gelatin, and to a hydrogel obtained by this process. The invention also relates to a process for consolidating the structure of a hydrogel comprising alginate and gelatin, said process comprising preparing the hydrogel, shaping it, then bringing it into contact with suitable consolidation agents. The present invention also relates to the hydrogel obtained by this process. In all these aspects of this invention, the hydrogel can further comprise fibrinogen and/or living cells.

IPC Classes  ?

• A61L 27/20 - Polysaccharides
• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/38 - Animal cells
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/58 - Materials at least partially resorbable by the body

Abstract

The present invention relates to three-dimensional body implants comprising a hydrogel comprising crosslinked alginate and gelatin, and in particular breast implants. The hydrogel of the implants according to the invention may further comprise fibrinogen. The implants according to the invention are acellular, that is to say free of cells during their manufacture.

IPC Classes  ?

• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/56 - Porous or cellular materials

Abstract

The present invention relates to novel short antimicrobial peptides derived from SHf, to pharmaceutical compositions comprising said peptides and to the uses thereof, in particular as medicament, disinfectant, preservative, agent preventing biofilm formation or pesticide.

IPC Classes  ?

• C07K 14/46 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

The present invention relates to a method and a kit for determining if a patient having pancreatic ductal adenocarcinoma (PDAC) is sensitive to a treatment. It further relates to a method for determining a suitable treatment for a patient having PDAC.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to a method for treating pulmonary alveolar proteinosis related to MARS gene mutations in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of supplementation of methionine and/or its derivatives. Pulmonary alveolar proteinosis related to mutations in the gene encoding the methionine tRNA synthetase is a severe, early-onset lung disease that also associates liver involvement, failure to thrive, and systemic inflammation. Inventors describe an infant affected by this disease who was successfully treated by oral methionine supplementation. After three months of treatment she was free of respiratory symptoms, inflammation and cholestasis resolved, and there was a catchup in growth. Her bronchoalveolar lavage fluid was free of extracellular lipoproteinaceous material. Functional assays on peripheral monocytes, initially altered, normalized. This study paves the way for similar strategies in other tRNA synthetase deficiencies.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The inventors previously demonstrated that mitochondrial VDAC1 directly induces Schwann cell demyelination via MAPK and c-jun activation after sciatic nerve injury and diabetic neuropathy and CMT1A. They found that reduction of mitochondrial calcium release by VDAC1 blocking strongly reduces the number of demyelinating Schwann cell in vivo and improve nerve conduction and neuromuscular activity in diabetic, Guillain-Barre syndrome and Charcot-Marie Tooth disease models. Herein, the inventors precisely map the binding region of the N-terminal HK-1 helix through an ala scan completed by a deletion study. Furthermore, they optimized the HK-derived peptide through stabilization of the helix by replacement of non- essential amino acids by the a-aminoisobutyric acid (Aib) known as a helix inducer. Additionally, they described an in-house cellular screening assay based on the ability of MJ to detach HK from VDAC that allows to determine the peptide potency. Overall, their data confirm that N-terminal HK derived peptides acting on VDAC are promising tools for the study of the demyelination process. Thus, the present invention refers to optimized HK-derived peptide and its use for treating peripheral demyelinating disease, myocardium diseases10 11, cancer 12,13-15, diabetes14 14-16, lupus-like diseases17,, non-alcoholic fatty liver disease24,25, chemoinduced neuropathy9 Alzheimer disease18 19, Parkinson disease20, Huntington disease21, ALS22,23 and more generally all neurodegenerative diseases linked to a protein aggregation 28.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

The present invention concerns a new gene therapy approach to increase light-sensitivity in degenerating cones in advanced stages of rod-cone dystrophy (RCD) mediated by G-protein-gated-K+ channel (GIRK), in particular GIRK1 F137S, activated by G proteins recruited by cone opsin expressed in degenerating cones.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 27/02 - Ophthalmic agents
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

Abstract

The present invention relates to a microfluidic chip capable of attracting and trapping a specific biological element, the chip comprising: - a reservoir (1) formed of a matrix comprising a chemoattractant compound capable of attracting the biological element - at least one microchannel array (2) arranged between the reservoir (1) and the outer medium (3) of the chip and allowing the chemoattractant compound to be moved toward the medium and the biological element present in the medium to be moved in the direction of the reservoir (1), characterised in that each microchannel is in the shape of a harpoon comprising at least two arrows (4) longitudinally spaced apart from each other and facing the reservoir, wherein each arrow comprises two limbs (5) each having a free end (6) forming an acute angle of between 10° and 80°, and wherein each arrow comprises two openings (7) communicating with a longitudinal portion of the microchannel and having a width of between 5 µm and 30 µm.

IPC Classes  ?

• A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• C07K 17/02 - Peptides being immobilised on, or in, an organic carrier

Abstract

The present application relates to novel bifunctional PROTAC-type compounds simultaneously binding the target protein PXR and E3-ubiquitin ligase, to a method for preparing same, and to uses thereof for treating cancers overexpressing PXR.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

The present disclosure relates to the use of mesoporous solids to control relative humidity in enclosed spaces while greatly reducing energy expenditure. The mesoporous solids are particularly suitable for controlling relative humidity in greenhouses.

IPC Classes  ?

• B01J 20/08 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group comprising bauxite
• B01D 53/26 - Drying gases or vapours
• B01J 20/10 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
• B01J 20/20 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
• B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties

Abstract

The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: (F), wherein W, X, Y and Z are as defined, for use in the treatment of Multiple Myeloma (MM).

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention concerns novel oxyfluoride derivatives and their preparation, as well as their uses as catalysts in electrochemistry, including the electrodes and electrochemical cells comprising them. These may be useful for hydrogen production.

IPC Classes  ?

• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• H01M 8/083 - Alkaline fuel cells
• H01M 8/086 - Phosphoric acid fuel cells [PAFC]
• H01M 8/1018 - Polymeric electrolyte materials
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• C25B 11/065 - Carbon
• C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
• B01J 27/12 - Fluorides
• C04B 35/553 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on fluorides
• H01M 8/10 - Fuel cells with solid electrolytes

Abstract

L'invention concerne le domaine des méta-matériaux acoustiques et en particulier un procédé de fabrication d'un méta-matériau acoustique (100) comportant une pluralité de colonnes (101) s'étendant à partir d'une base commune, ainsi que le méta-matériau acoustique (100) obtenu par ce procédé. Ce procédé comprend une étape fabrication additive d'un moule (210) par dépôt d'une pluralité de strates empilés (203) comprenant chacun une pluralité de cellules (204) périodiquement répétées, séparées par des parois (205), les cellules (204) de la pluralité de strates empilés (203) étant alignées de manière à former des canaux (206), une étape de remplissage des canaux (206) avec un matériau fluide (220), une étape de solidification du matériau fluide (220), et une étape d'élimination du moule (210).

IPC Classes  ?

• B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing
• B29C 39/10 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor for making articles of definite length, i.e. discrete articles incorporating preformed parts or layers, e.g. casting around inserts or for coating articles

Abstract

L'invention concerne un méta-matériau acoustiques (100), ainsi qu'un procédé pour sa fabrication. Le méta-matériau acoustique comprend une pluralité de canaux (101) ayant chacun une même section transversale avec un rayon hydraulique entre 5 et 300 pm, disposés avec un espacement périodique (t) entre canaux adjacents entre 2 et 600 pm. On peut ainsi obtenir un réseau hautement dense de micro-canaux acoustiques pouvant offrir une absorption et/ou impédance acoustiques optimales sur une large bande de fréquences. Son procédé de fabrication est un procédé de fabrication additive comprenant plusieurs étapes consécutives de dépôt de matériau pour former, dans chaque étape, une couche (203) comportant une pluralité de cellules (204) périodiquement répétées, séparées par des parois (104). Les couches (203) déposées dans les étapes consécutives de dépôt de matériau sont empilées avec leurs cellules (204) respectives alignées de manière à former les canaux (101).

IPC Classes  ?

• G10K 11/175 - Methods or devices for protecting against, or for damping, noise or other acoustic waves in general using interference effects; Masking sound
• B64C 1/40 - Sound or heat insulation
• B64D 29/00 - Power-plant nacelles, fairings, or cowlings
• G10K 11/162 - Selection of materials

Abstract

An implant for heart valve repair, the implant comprising: a clamp movable between an open position and a closed position in which the clamp is able to grasp a leaflet of a heart valve, so as to fix the implant on the leaflet; and a shutter comprising a structure adapted to pass automatically from a contracted configuration to an expanded configuration in which 5 the shutter is able to fill at least partially an opening portion remaining between the leaflet and at least one further leaflet of the heart valve of the heart valve, when the implant is attached to one leaflet, so as to limit a backflow of blood through the opening portion when the heart valve closes, and wherein the structure is curved in two directions perpendicular to each other in the expanded configuration.

IPC Classes  ?

• A61F 2/24 - Heart valves

Abstract

The invention concerns a binder composition comprising: a. between 1% and 30% in dry weight of Portland cement, lime or a mixture thereof; b. between 1% and 40% in dry weight of ground granulated blast furnace slag; c. between 20% and 50% in dry weight of at least one pozzolanic material; d. between 20% and 65% in dry weight of at least one filler; e. between 0.5% and 10% in dry weight, relative to the total weight of components a, b c and d, of at least one activator; f. between 0.05% and 1.5% in dry weight, relative to the total weight of components a, b, c and d, of at least one water reducer polymer; said filler being a particles mixture of: - between 10% and 90% in weight, in respect with the total weight of the filler, of particles having a d50 greater than or equal to 0,05?m and strictly less than 8?m, and - between 10% and 90% in weight, in respect with the total weight of the filler, of particles having a d50 greater than or equal to 8?m and strictly less than 200?m.

IPC Classes  ?

• C04B 28/04 - Portland cements
• C04B 28/12 - Hydraulic lime

Abstract

The above objectives are reached thanks to a binder composition comprising: a. between 1% and 30% in dry weight of at least one lime source; b. between 5% and 75% in dry weight of ground granulated blast furnace slag; c. between 20% and 90% in dry weight of at least one filler; d. between 0.1% and 5% in dry weight, relative to the total weight of components a, b and c, of SO3-; e. between 0.1% and 1% in dry weight, relative to the total weight of components a, b and c, of at least one water reducer polymer; f. between 0% and 2% in dry weight, relative to the total weight of components a, b and c, of at least one activator different from d.; said ground granulated blast furnace slag being a particles mixture of : - between 10% and 100% in weight, in respect with the total weight of the ground granulated blast furnace slag, of particles having a d50 greater than or equal to 1µm and strictly less than 5µm, - between 0% and 90% in weight, in respect with the total weight of the ground granulated blast furnace slag, of particles having a d50 greater than or equal to 5µm and preferably less than 15µm, said filler being a particles mixture of : - between 10% and 90% in weight, in respect with the total weight of the filler, of particles having a d50 greater than or equal to 0,05µm and strictly less than 8µm, and - between 10% and 90% in weight, in respect with the total weight of the filler, of particles having a d50 greater than or equal to 8µm and strictly less than 200µm.

IPC Classes  ?

• C04B 28/08 - Slag cements
• C04B 40/06 - Inhibiting the setting, e.g. mortars of the deferred action type containing water in breakable containers

Abstract

The invention relates to a method for releasing platelets from megakaryocytes contained in a fluid (F), said method being carried out by means of a system (1) comprising two concentric cylinders (11, 13), an inner cylinder (11) comprising a cylindrical wall (12) and a hollow outer cylinder (13) located radially external to the inner cylinder (11), said outer cylinder (13) comprising a cylindrical wall (14) of a base (13a) at which said second cylinder is closed, said cylinders (11, 13) being separated by a space (15) devoid of any mechanical parts, said space (15) being intended to receive the fluid (F), said method comprising the following steps: (100) supplying said space (15) with a fluid (F) comprising megakaryocytes, (200) rotating the inner cylinder (11) about its axis, the outer cylinder (13) being stationary, or moving the two cylinders (11, 13) in opposite directions about their axes, so as to generate an at least partially turbulent flow of fluid (F) in said space (15) and obtain a second fluid (F') enriched in platelets.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The present invention relates to ureal derivatives of formula (I) and pharmaceutical compositions comprising such derivatives for use in the treatment of uveal melanoma.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61P 35/00 - Antineoplastic agents
• C07D 235/30 - Nitrogen atoms not forming part of a nitro radical
• C07D 277/82 - Nitrogen atoms
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention relates to the prevention and/or treatment of a neurodevelopmental disorder or a neuropsychiatric disorder comprising administering a therapeutically effective amount of fasudil or a derivative thereof or a pharmaceutical composition comprising fasudil or a derivative thereof, in a subject in need thereof.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention pertains to enzyme-triggered self-reacting arm compounds, chemical intermediates used for preparing such compounds and uses thereof, specifically in prodrug design and conjugation technologies. The present invention also relates to a Ligand-Drug-Conjugate (LDC) comprising such enzyme-triggered self-reacting arms.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07D 455/03 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
• C07D 471/14 - Ortho-condensed systems
• C07D 498/14 - Ortho-condensed systems
• C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings

Abstract

The present invention relates to an antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is a topoisomerase I inhibitor, particularly exatecan.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an immunogenic composition containing at least one antigen and at least one adjuvant comprising at least one Metal-Organic Framework comprising an inorganic part based on aluminum and an organic part based on polydentate ligand chosen from fumarate, muconate, mesaconate, oxalate, oxaloacetate, succinate, malate, citrate, aconitate, isophthalate, substituted isophthalate, 2,5-thiophenedicarboxylate, 2,5-furandicarboxylate, trimesate, trimellitate and pyromellitate, said antigen being immobilized at least within said Metal-Organic Framework.

IPC Classes  ?

• A61K 39/08 - Clostridium, e.g. Clostridium tetani
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/04 - Antibacterial agents

Abstract

While 3D ultrasound imaging is becoming a powerful tool in medical field, the main drawback is the difficulty to image large 3D volume, mainly related to the dimensions of the 2D array of transducers. In order to not lose in spatial resolution, it is necessary to use an array of transducers, wherein the size of the transducers does not exceed the wavelength of the ultrasound wave. Such requirement leads to dimensions of array for imaging large 3D volume which are not reachable or at too high cost with the current technology. The present disclosure overcomes the above technology limitation by using greater transducers, and where each transducer has a reception surface with a curved shape or is fitted with an acoustic lens. Such configuration of transducers leads to 2D array of transducers suitable for imaging large 3D volume, as a brain or a heart, with high resolution and high sensitivity.

IPC Classes  ?

• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging

Abstract

The present invention relates to a method for preparing a compound of formula (I) comprising the following steps: (i) reacting a compound of formula (II) with a compound of formula (III), to form the hydrochloride salt of the compound of formula (I), wherein the molar ratio of the compound of formula (II) vs. the compound of formula (III) is from 1.00:0.80 to 1.00:1.20, and no metal catalyst is present, and (ii) recovering the compound of formula (I) in the form of a free base through addition of a base. The present invention also relates to a powder obtained by said method and a powder comprising a compound of formula (I) which is characterized by a particle size distribution with specific D50, D90 and/or D10 values, and a pharmaceutical composition comprising said powders and at least one pharmaceutically acceptable excipient.

IPC Classes  ?

• C07D 215/38 - Nitrogen atoms

Abstract

The invention relates to MnTBAP or Mn(III) substituted pyridylporphyrin (MnP) compounds selected among MnTE-2-Pyp5+, MnTEHex-2-Pyp5+ and MnTnBuOE-2- Pyp5+ for use in treating sepsis and/or reversing sepsis-induced microglial cells alteration(s), and/or reversing associated long-term cognitive impairment in a subject diagnosed with sepsis or sepsis-associated encephalopathy (SAE), and/or treating long-term cognitive impairment in a subject suffering from sepsis or sepsis- associated encephalopathy (SAE).

IPC Classes  ?

• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 31/02 - Local antiseptics

Abstract

The present invention relates to a human macrophage for use in cancer therapy, said human macrophage comprising at least one mutation in both alleles of a chromosomal gene, wherein said macrophage is resistant to tumor-induced reprogramming and/or shows anti-tumor activity. The human macrophage of the invention demonstrates typical markers of an M1 macrophage, such as the presence of MHC class II proteins, even after having been cultured in an environment which promotes M2-polarization, such as in the presence of M-CSF and/or IL4 and/or IL13. The invention also relates to a collection of human macrophages of the invention, to their use in medicine, and in particular to their use in cancer therapy such as the treatment of solid tumors as a preferred example.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• C12N 5/0786 - Monocytes; Macrophages

Abstract

The invention provides human phagocytic cells which are not tumorigenic, yet still capable of cell division ex-vivo, such as in cell culture. A culture containing these cells can be expanded manyfold, that is the cell number in such a culture can be increased by a factor of 10 or more. The cells show characteristics of functional phagocytes in a differentiated state and are capable to alleviate pathological defects in in vivo models.

IPC Classes  ?

• C12N 5/0786 - Monocytes; Macrophages
• C12N 5/0784 - Dendritic cells; Progenitors thereof
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells

Abstract

The present invention relates to a compound having the following formula (I) wherein: - R and R' are, independently from each other, H or (C1-C6)alkyl groups, or form together with the carbon atoms carrying them a (C6-C10)aryl group; - R2 is selected from the group consisting of: H, (C1-C6)alkyl group, halo(C1-C6)alkyl group, aryl, and heteroaryl; - A1 is a linker; - R'' is either a group (A-1) or a group (A-2) for use in the treatment of a brain disorder involving modified 5-HT7R-mediated signaling, especially for use in the treatment of pain or inflammation or in the treatment of multiple sclerosis, or for use to induce hypothermia.

IPC Classes  ?

• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 233/70 - One oxygen atom
• C07D 235/26 - Oxygen atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 487/04 - Ortho-condensed systems
• C07D 487/10 - Spiro-condensed systems

Abstract

The present invention relates to a method for the selective analysis of a subpopulation of cells or organelles based determining the level of at least one cell or organelle marker, via the implementation of an adapted DNA toolbox able to convert the presence of a cell or organelle marker into a signal. This method is particularly useful for selecting cells or organelles having a phenotype of interest, analyzing the proteins of said cells or organelles and/or sequencing the DNA and/or RNA of said cells. The present invention also relates to a kit for implementing the method of selective analysis of cells or organelles as defined above.

IPC Classes  ?

• C12Q 1/6804 - Nucleic acid analysis using immunogens
• C12Q 1/682 - Signal amplification

Abstract

A system for controlling the activation/deactivation of an electromagnetic shielding screen (11a, 11b, 11c, 11d) of a porthole or a protective window of an optoelectronic equipment, which includes, a radiofrequency electromagnetic sensor (1), with a bandwidth adapted to a cut-off band of said shielding screen corresponding to a range of electromagnetic fields to be blocked, connected to a detector-rectifier (2) with a sensitivity higher than a minimum value of the power of an electromagnetic field to be blocked by means of said shielding screen and a device (13, 14, 15, 16) for activating/deactivating said electromagnetic shielding screen, said detector-rectifier being configured, in the presence of the electromagnetic field with a power exceeding said minimum value, to activate said device (13, 14, 15, 16) for activating/deactivating the electromagnetic shielding screen by capturing the electromagnetic energy supplied by said electromagnetic fields with a power exceeding said minimum value. Figure of the abstract: Figure 1

IPC Classes  ?

• G01J 5/06 - Arrangements for eliminating effects of disturbing radiation; Arrangements for compensating changes in sensitivity

Abstract

Composant optique (5) comprenant un substrat (6) en un matériau ayant un taux prédéterminé de transmission de rayonnements ayant une longueur d'onde comprise dans une bande prédéterminée de longueurs d'onde, et un revêtement (7) s'étendant sur une surface (6') du substrat (6). Le revêtement (7) comprend une matrice (8) à base d'au moins un polymère dans laquelle sont noyées des nanoparticules (9), le composant optique (5) ayant au total un taux de transmission suffisant pour l'application pour des longueurs d'ondes comprises dans la bande prédéterminée de longueurs d'onde.

IPC Classes  ?

• G02B 1/14 - Protective coatings, e.g. hard coatings
• G01J 1/04 - Optical or mechanical part

Abstract

The invention relates to a composition (1) for manufacturing an electrode (2), the composition comprising an electrically conductive compound made from carbon, at least one species suitable for forming a catalyst, and cellulose microfibrils encapsulating chitosan. The cellulose microfibrils create a fibrous mesh binding the composition while limiting the coating of the catalyst. The catalyst therefore remains accessible to the surrounding environment, in order to allow redox reactions at the electrode. The electrochemical performances of the electrode are thus improved. The composition (1) is moreover particularly suitable for the shaping (40) of electrodes by 3D printing.

IPC Classes  ?

• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 4/88 - Processes of manufacture
• H01M 4/90 - Selection of catalytic material
• H01M 8/16 - Biochemical fuel cells, i.e. cells in which microorganisms function as catalysts

Abstract

This method for manufacturing a flux detector of a first and a second incident ionising radiation comprises: - determining (92) the abscissa em of a point of intersection between a first and second curve, the first and second curves representing the change in the number of photons or electrical charges generated per second by a transducer material as a function of the total thickness of an amplifier material when the transducer material is irradiated, through this thickness of transducer material, by, respectively, the first and second incident ionising radiation, then - selecting (94) a total thickness of the amplifier material between 0.9em and 1.1em and producing the detector with this selected thickness of amplifier material.

IPC Classes  ?

• G01T 1/20 - Measuring radiation intensity with scintillation detectors

Abstract

The invention relates to a synthetic sialoside presenting the formula (I): Neu5Ac-a2-6-R1(R2)[GlcNAcß1-4]n-GlcNAc Formula wherein: - GlcNAc is N-acetylglucosamine; - GlcNAcß1-4 is a N-acetylglucosamine unit linked with a ß1-4 link; - n is superior or equal to 1; - R1 is a glycan structure comprising at least one galactose (Gal); and - R2 is chosen among the following groups: H, fucose linked with a a1-3 link (Fuca1-3) or a a1-4 link (Fuca1-4).

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups ; Derivatives thereof
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Abstract

The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A01N 1/02 - Preservation of living parts
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 209/12 - Radicals substituted by oxygen atoms

Abstract

The present invention relates to a synergistic combination of an FXR agonist and interferon for the treatment of hepatitis B.

IPC Classes  ?

• A61K 31/42 - Oxazoles
• A61K 31/46 - 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• A61K 38/21 - Interferons
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 31/20 - Antivirals for DNA viruses

Abstract

The invention relates to recombinant measles virus expressing Immunodeficiency virus (IV) or HTLV polypeptides, and concerns in particular immunogenic immunodeficiency virus particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of at least one immunodeficiency virus or Human T-lymphotropic virus. These particles may be recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by HIV or HTLV.

IPC Classes  ?

• C12N 15/49 - Lentiviridae, e.g. immunodeficiency viruses such as HIV, visna-maedi virus, equine infectious anaemia virus
• A61K 39/165 - Mumps or measles virus
• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 31/12 - Antivirals
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/45 - Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
• C12N 15/86 - Viral vectors
• A61K 35/76 - Viruses; Subviral particles; Bacteriophages

Abstract

A microfluidic device (10) comprising: - a first wall (12) comprising a first substrate (14) on which a plurality of closed patterns (16) is grafted, - a second wall (18), facing the first wall (12), comprising a second substrate (20), - a plurality of nucleic acids (22) grafted either on the first substrate (14) or on the second substrate (20), wherein each nucleic acid (22) comprises a barcode that encodes the position of the nucleic acid on said first (14) or second (20) substrate, wherein at least the plurality of closed patterns (16) or the second substrate (20) is made of an actuatable hydrogel which is swellable between a retracted state and a swollen state in which the closed patterns (16) and the second substrate (20) come into contact.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• C12Q 1/6813 - Hybridisation assays

Abstract

The present invention relates to a pharmaceutical composition characterised in that it contains at least one compound with the following formula (I) as active ingredient: (I) in which R1 is chosen from H, SO3-, R2 is chosen from H and COCH3, R3 is chosen from H, COCH3, benzyl, SO3- and pharmaceutically acceptable salts of said compounds - with the exception of the compound of formula (I) in which R1=SO3- and R2= COCH3 and R3=H and of the sodium salt of said compound - and at least one pharmaceutically acceptable excipient. The present invention also relates to an associated kit comprising a biocompatible medium.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 47/04 - Non-metals; Compounds thereof
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

One aspect of the invention relates to a device for measuring a particle beam, comprising a front face (F) and a rear face (B) as well as: a first portion, referred to as the central portion (PC), comprising means for forming a space charge region (ZCE) through which a particle beam (FS) to be measured passes, charge carriers of a first type and a second type being generated by the beam (FS) when the latter passes through the space charge region (ZCE); a second portion, referred to as the peripheral portion (PP), comprising means for collecting at least one type of charge carrier from among the first type or the second type of charge carriers generated in the space charge region (ZCE); the central portion (PC) having a maximum thickness less than or equal to the thickness of the peripheral portion (PP), the peripheral portion (PP) surrounding the central portion (PC) such that a particle beam (FS) can pass through the central portion (PC) without passing through the peripheral portion (PP), the device being characterised in that it comprises, in a region of the central portion leading to the rear face (B), a layer of a porous material forming a porous region such that the effective thickness perceived by the beam when it passes through the device via the porous region along an axis normal to the front face (F) is less than the thickness of the central portion (PC).

IPC Classes  ?

• H01L 31/115 - Devices sensitive to very short wavelength, e.g. X-rays, gamma-rays or corpuscular radiation

Abstract

The present invention relates to a polypeptide X1X2-RK-X3X4-KK-X5X6X7X8X9X10-KR-X11X12 (SEQ ID N°1) able to bind selectively to cells expressing proteoglycans comprising glycosaminoglycans as heparin or heparan sulfate. The linkage of said polypeptide to an internalization peptide enables the polypeptide to be internalized. The present invention further relates to a conjugated polypeptide comprising said polypeptide and a biomarker, to a cell penetrating polypeptide comprising said polypeptide, optionally a linker and a cell internalization peptide and a chimeric polypeptide comprising said cell penetrating polypeptide and one or more biological cargos.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

According to an aspect, the present description relates to an ultrasound probe holding device (101) configured to attach to the head of an infant for transfontanellar imaging, comprising a head pad (110) configured to be in contact with the head of the infant and comprising a central opening (115), wherein the head pad is configured to receive an ultrasound probe; a pad squeezer (120), comprising a central opening (125) and configured to cooperate with the head pad to allow an axial guidance of the head pad along a guidance axis (D) substantially perpendicular to a surface tangent to the head of the infant; a device holder (150) configured to be attached to the head of the infant and exert a downward force on the pad squeezer, along said guidance axis; and repellent means configured to exert a repellent force between the pad squeezer and the head pad when the device holder exerts the downward force on the pad squeezer.

IPC Classes  ?

• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
• A61B 5/369 - Electroencephalography [EEG]

Abstract

The invention relates to a system (10) for treating a target (Tar) by laser shock in a regime of confinement in a liquid (Liq), the system comprising a pulsed laser generating a beam (B) having a pulse duration of between 1 ns and 30 ns and a wavelength, a concentrating optical device (COD) having a focal length and configured to concentrate the beam (B) on the surface (St) of the target (Tar), the incident laser beam (B) on the concentrating device having a diameter (D), a tank (TK) filled with said liquid (Liq) having a refractive index n, a desired value of the diameter (D) of the beam on a surface (St) of the target being predetermined and named Dst, a thickness (e) of liquid (Liq) passed through by the beam (B) before reaching the surface (St) of the target (Tar) being chosen such that a laser intensity on the surface of the liquid (Isl) is less than or equal to a laser intensity on the surface of the target (Ist) divided by 2.

IPC Classes  ?

• B23K 26/00 - Working by laser beam, e.g. welding, cutting or boring
• B23K 26/0622 - Shaping the laser beam, e.g. by masks or multi-focusing by direct control of the laser beam by shaping pulses
• B23K 26/122 - Working by laser beam, e.g. welding, cutting or boring in a special environment or atmosphere, e.g. in an enclosure in a liquid, e.g. underwater
• B23K 26/356 - Working by laser beam, e.g. welding, cutting or boring for surface treatment by shock processing
• B23K 26/06 - Shaping the laser beam, e.g. by masks or multi-focusing
• B23K 26/12 - Working by laser beam, e.g. welding, cutting or boring in a special environment or atmosphere, e.g. in an enclosure

Abstract

The invention concerns a system for controlling the temperature of a microfluidic chip comprising a Peltier module (10) having a cold face (10a) and a hot face (10b) and connected to a power generator (11), a thermal regulation device (12) having a thermal regulated face (12a) applied against one of the faces of the Peltier module, at least one temperature sensor (17) being applied on the other face of the Peltier module and being intended to be applied against one of the main faces of a microfluidic chip and control means (18) configured to control the power generator (11) of the Peltier module depending on a temperature of the face of the Peltier module provided with said at least one temperature sensor and at least one temperature setting information selected from a target temperature and a target temporal temperature profile to regulate a temperature of the face of the Peltier module to said temperature setting information.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• B01L 7/00 - Heating or cooling apparatus; Heat insulating devices
• B01L 9/00 - Supporting devices; Holding devices

Abstract

The present invention relates to an in vitro method for preparing a composition comprising mesenchymal stem cells (MSCs) intended for treating ischemia-reperfusion injury, comprising: a) providing MSCs; b) cultivating MSCs in a culture medium comprising a PPAR?/? agonist; c) removing the culture medium and washing the MSCs; and d) collecting MSCs in a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier does not contain a PPAR?/? agonist. It further relates to MSCs obtained using the method of the invention, as well as their use as a medicament, preferably in the treatment or prevention of ischemia-reperfusion injury, wherein the method of treatment or prevention does not comprise administering a PPAR?/? agonist to the subject.

IPC Classes  ?

• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C12N 5/0775 - Mesenchymal stem cells; Adipose-tissue derived stem cells
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to a cell culture comprising a placental cell and a culture medium consisting of minimal essential nutriments and a low amount of serum. The invention also relates to a method using the cell culture for identifying endocrine disruptor.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissues; Foetal cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

The present invention relates to trimeprazine derivatives of formula (I) for use for treating a neuropsychiatric disorder chosen among an intellectual disability (ID), preferably fragile X syndrome (FXS), autism spectrum disorders (ASD), and attention deficit hyperactivity disorder (ADHD). The invention also relates to pharmaceutical compositions for use comprising such derivatives.

IPC Classes  ?

• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61P 25/00 - Drugs for disorders of the nervous system